{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:48:33Z","timestamp":1790171313820,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.trecan.2017.01.004","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T01:15:49Z","timestamp":1485825349000},"page":"161-163","source":"Crossref","is-referenced-by-count":23,"title":["IFN Signaling and ICB Resistance: Time is on Tumor\u2019s Side"],"prefix":"10.1016","volume":"3","author":[{"given":"Alejandro","family":"L\u00f3pez-Soto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Segundo","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia R.","family":"Folgueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2017.01.004_bib0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.trecan.2017.01.004_bib0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc.2016.2","article-title":"Acquired resistance to immunotherapy and future challenges","volume":"16","author":"Restifo","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.trecan.2017.01.004_bib0015","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2017.01.004_bib0020","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trecan.2017.01.004_bib0025","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.trecan.2017.01.004_bib0030","doi-asserted-by":"crossref","first-page":"9010","DOI":"10.1073\/pnas.0901329106","article-title":"Impaired interferon signaling is a common immune defect in human cancer","volume":"106","author":"Critchley-Thorne","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trecan.2017.01.004_bib0035","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1053\/j.seminoncol.2015.02.012","article-title":"Immune checkpoint blockade and interferon-alpha in melanoma","volume":"42","author":"Rafique","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.trecan.2017.01.004_bib0040","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.trecan.2017.01.004_bib0045","doi-asserted-by":"crossref","first-page":"e1008824","DOI":"10.1080\/2162402X.2015.1008824","article-title":"Interferon-gamma-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression","volume":"4","author":"Bellucci","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2017.01.004_bib0050","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803317300213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803317300213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T19:23:57Z","timestamp":1536089037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803317300213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S2405803317300213"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2017.01.004","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}